Literature DB >> 3891066

Immunohistochemical demonstration of follicular dendritic cells in bone marrow involvement of B-cell chronic lymphocytic leukemia.

M Chilosi, G Pizzolo, F Caligaris-Cappio, A Ambrosetti, F Vinante, L Morittu, F Bonetti, L Fiore-Donati, G Janossy.   

Abstract

Using a sensitive immunohistochemical technique and a specific monoclonal antibody (RFD-3), follicular dendritic cells (FDC) have been demonstrated in a significant proportion (6/12) of bone marrow samples from patients with nodular marrow involvement of B-cell chronic lymphocytic leukemia (B-CLL). In all cases with "packed marrow" involvement and advanced stages of disease the FDC were absent. As these accessory cells are normally present only in the lymph nodes, their presence in the bone marrow is in accord with the view that B-CLL might be the malignancy of an immature subpopulation of lymph node lymphocytes that invade the bone marrow.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3891066     DOI: 10.1002/1097-0142(19850715)56:2<328::aid-cncr2820560221>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells.

Authors:  Iris Gehrke; Rajesh Kumar Gandhirajan; Simon Jonas Poll-Wolbeck; Michael Hallek; Karl-Anton Kreuzer
Journal:  Mol Med       Date:  2011-04-14       Impact factor: 6.354

Review 2.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

Review 3.  Growth and survival of B-chronic lymphocytic leukaemia cells.

Authors:  O Söderberg
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

4.  Benign and malignant (B cell) focal lymphoid aggregates in bone marrow trephines shown by means of an immunogold-silver technique.

Authors:  G Sangster; J Crocker; P Nar; M J Leyland
Journal:  J Clin Pathol       Date:  1986-04       Impact factor: 3.411

Review 5.  Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells.

Authors:  Rajendra N Damle; Carlo Calissano; Nicholas Chiorazzi
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

6.  Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.

Authors:  Rashmi Gupta; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2018-08-01       Impact factor: 5.422

7.  Isolation of multicellular complexes of follicular dendritic cells and lymphocytes: immunophenotypical characterization, electron microscopy and culture studies.

Authors:  M G Ennas; M Chilosi; A Scarpa; M S Lantini; G Cadeddu; L Fiore-Donati
Journal:  Cell Tissue Res       Date:  1989-07       Impact factor: 5.249

Review 8.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

9.  Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region.

Authors:  L Flenghi; B Bigerna; M Fizzotti; S Venturi; L Pasqualucci; S Pileri; B H Ye; M Gambacorta; R Pacini; C D Baroni; E Pescarmona; I Anagnostopoulos; H Stein; G Asdrubali; M F Martelli; P G Pelicci; R Dalla-Favera; B Falini
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

10.  Evaluation of Prognostic Impact of Soluble CD14 in B-Chronic Lymphocytic Leukemia.

Authors:  Waiel Al-Kahiry; Homam Sharshira; Amal Ghanem; Maha El-Gammal; Irene Lewis Mikhael
Journal:  Indian J Hematol Blood Transfus       Date:  2016-11-16       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.